Alcobra's metadoxine extended-release (MDX) already was walking a tightrope as a potential new therapeutic approach for adult ADHD, but a Phase III clinical trial miss reported Jan. 17 is leading the Israeli biotech to shutter that program and consider its strategic alternatives.
Alcobra revealed only a week earlier that it would conduct a six-month Phase I safety study of MDX to seek...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?